Compare KEN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | TGTX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.9B |
| IPO Year | 2014 | 2008 |
| Metric | KEN | TGTX |
|---|---|---|
| Price | $81.91 | $36.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.80 |
| AVG Volume (30 Days) | 18.4K | ★ 1.7M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.64% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | N/A | $26.69 |
| P/E Ratio | ★ $9.21 | $12.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.60 | $25.37 |
| 52 Week High | $89.89 | $46.48 |
| Indicator | KEN | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 73.74 |
| Support Level | $78.28 | $33.58 |
| Resistance Level | $86.05 | $37.11 |
| Average True Range (ATR) | 2.24 | 1.16 |
| MACD | -0.44 | 0.20 |
| Stochastic Oscillator | 23.20 | 95.07 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.